Sanegene Bio has entered into a global research collaboration and licence agreement with Genentech, a member of the Roche Group, to co-develop an RNA interference (RNAi) therapy. Under the agreement, Sanegene will grant Genentech exclusive global rights to develop and commercialise the candidate. Sanegene will lead the early research, while Genentech will be responsible for subsequent clinical development and commercialisation activities. Sanegene will receive an upfront payment of USD 200 million and is eligible for up to USD 1.5 billion in development and sales milestone payments, plus tiered royalties.

Founded in 2021, Sanegene is an RNAi-focused company that has raised over USD 110 million in a Series B financing round. The company leverages its proprietary LEAD delivery platform, designed for efficient, tissue-selective targeting of RNAi drugs. This deal follows a separate strategic RNAi collaboration Sanegene signed with Eli Lilly in November 2025, which is valued at up to USD 1.2 billion.

According to PharmCube's NextBiopharm® database, this marks Genentech's 10th-largest deal. Click here to request a free trial for NextBiopharm®.